An observational study in Stomach Neoplasms, Gastric Adenocarcinoma and Metastatic Gastric Cancer, sponsored by Fundación Santa Fe de Bogota. Recruiting at 4 sites in Colombia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Fundación Santa Fe de Bogota · Observational
How we know · 8 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Stomach Neoplasms with a site in Colombia — 7 open to participants now, 8 under way, 2 of them phase 3. Stomach Neoplasms · Colombia.
Among the 22 studies in Stomach Neoplasms with a site in Colombia, this one is one of 5 that started in 2026, is one of 7 observational ones, and was the 21st registered.
3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.
Browse Stomach Neoplasms studies →7 of the 22 studies in Stomach Neoplasms with a site in Colombia are open now. Recruiting first, the newest first:
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Sites in Colombia
Ages 18+
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Sites in Colombia
Ages 18+ · Healthy volunteers
Bristol-Myers Squibb · Sites in Colombia, United States, Argentina and 17 more countries
Ages 18+
Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Sites in Colombia
Ages 18+ · Healthy volunteers
University of Latvia · Sites in Colombia, Brazil, Chile and 2 more countries
Ages 18+
A study can be open while its sites in Colombia have not opened yet or have stopped. Only those recruiting at a site in Colombia →
Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 9
First in 2002; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 278 across 792 observational studies indexed under Stomach Neoplasms.
Median enrollment 515 across the 15 interventional studies, 150 across the 7 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 22 have an industry lead sponsor. The 10 most frequent:
Fundación Santa Fe de Bogota is the lead sponsor of 27 studies on the registry; 11 are open to participants now.
Fundación Santa Fe de Bogota has 2 studies filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Stomach Neoplasms with a site in Colombia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07816263Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloGuaraná Supplementation for Cancer-Related Fatigue | 2027-01-18 |
| NCT07856212Fundación Santa Fe de BogotaMaintenance Therapy in Metastatic Gastric Cancer: A Multicenter Retrospective Study in Colombia | 2027-03-01 |
| NCT07741435Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloMethylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia | 2027-06-04 |
| NCT07859254Fundación Santa Fe de BogotaPathological Response to Perioperative FLOT in Gastric Adenocarcinoma | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Stomach Neoplasms with a site in Colombia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metastatic gastric cancer has a poor prognosis, and the cumulative toxicity of first-line platinum and fluoropyrimidine chemotherapy limits how long treatment can be continued. Maintenance therapy, in which patients whose disease is at least stable after induction chemotherapy continue on a less toxic regimen, is increasingly used, most often with fluoropyrimidines (capecitabine, 5-fluorouracil or S-1) and, in selected molecular subgroups, with immunotherapy or targeted therapy. Evidence on the outcomes of these strategies in Latin American patients is scarce.
This multicenter retrospective study will review the medical records of adults with metastatic gastric cancer treated between 2013 and 2023 at four high-complexity cancer centers in Bogotá, Colombia, who received maintenance therapy after achieving at least stable disease with induction chemotherapy. The study will describe the demographic, clinical, pathological and molecular characteristics of these patients and estimate overall survival, progression-free survival, treatment response, toxicity and mortality. The investigators will not assign or modify any treatment.
Background: Gastric cancer is the fifth most frequent cancer and the third cause of cancer-related death worldwide, with high incidence in Asia and Latin America. In Colombia, most cases are diagnosed at advanced stages. Platinum and fluoropyrimidine combinations remain the standard first-line treatment for metastatic disease, but the optimal duration of first-line chemotherapy and the role of maintenance strategies are not clearly established. The randomized phase II AIO MATEO trial showed that S-1 maintenance after induction chemotherapy achieved overall survival comparable to continued chemotherapy with less toxicity. Immunotherapy and targeted therapies (such as trastuzumab in HER2-positive disease) are also used in the maintenance setting in selected molecular subgroups. No Colombian data exist on the outcomes of these maintenance strategies.
Design: Observational, retrospective, multicenter cohort study based on review of medical records at four high-complexity cancer centers in Bogotá, Colombia: Hospital Universitario Fundación Santa Fe de Bogotá (coordinating center, through the Instituto de Cáncer Carlos Ardila Lülle), Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Clínica del Country and Los Cobos Medical Center.
Population: Adults (older than 18 years) with metastatic gastric cancer diagnosed and treated between 2013 and 2023 who achieved at least stable disease by RECIST after induction chemotherapy, with ECOG performance status of 2 or less, and who subsequently received maintenance therapy. All eligible patients will be included (census sampling); no sample size calculation is required.
Data collection: Data will be abstracted from institutional medical records into a single REDCap database hosted by Fundación Santa Fe de Bogotá. Each center will have restricted user accounts limited to its own patients. Records will be coded with an alphanumeric identifier, and the identification key will remain locally at each center and will not be uploaded. Variables include demographic and clinical characteristics, comorbidities, Helicobacter pylori status, histology (WHO and Lauren classifications, differentiation), molecular markers (microsatellite instability, PD-L1, HER2), AJCC 8th edition staging, induction and maintenance regimens and number of cycles, immunotherapy and targeted therapy, adverse drug reactions, laboratory values and tumor markers, dates of progression and relapse, vital status and cause of death.
Statistical analysis: Qualitative variables will be summarized with absolute and relative frequencies and quantitative variables with means and standard deviations or medians and interquartile ranges according to their distribution. Overall and progression-free survival will be estimated with the Kaplan-Meier method and reported as medians and survival rates. Exploratory comparisons of outcomes among maintenance types (fluoropyrimidines, immunotherapy, targeted therapy) will use bivariate tests and adjusted multivariable models, considering the molecular profile as a potential effect modifier. Analyses will be performed with IBM SPSS Statistics 25.
Ethics: The study is classified as research without risk under Colombian Resolution 8430 of 1993, and individual informed consent is not required for this retrospective record review. The protocol was approved by the Comité Corporativo de Ética en Investigación of Fundación Santa Fe de Bogotá (CCEI-18065-2025) and by the ethics committees of the participating institutions. Data will be handled in accordance with the Declaration of Helsinki and Colombian Law 1581 of 2012 on personal data protection, stored securely for five years and then destroyed.
Adults with metastatic gastric cancer diagnosed and treated between 2013 and 2023 at four high-complexity cancer centers in Bogotá, Colombia (Hospital Universitario Fundación Santa Fe de Bogotá, Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo, Clínica del Country and Los Cobos Medical Center) who received maintenance therapy after achieving at least stable disease with induction chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fluoropyrimidine Maintenance Therapy · Drug: Immune Checkpoint Inhibitor Maintenance · Drug: Targeted Therapy Maintenance
Fluoropyrimidine-based maintenance therapy (capecitabine, 5-fluorouracil or S-1) administered after induction chemotherapy in routine clinical practice. The study does not assign or modify treatment; exposure data are abstracted retrospectively from medical records.
Also known as: Capecitabine, 5-Fluorouracil, S-1
Immune checkpoint inhibitors (such as nivolumab, pembrolizumab or atezolizumab) administered as part of maintenance therapy in routine clinical practice. The study does not assign or modify treatment.
Also known as: Nivolumab, Pembrolizumab, Atezolizumab
Targeted therapy (such as trastuzumab in HER2-positive disease) administered as part of maintenance therapy in routine clinical practice. The study does not assign or modify treatment.
Also known as: Trastuzumab
This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., AtezolizumabStudies of AtezolizumabAtezolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Overall Survival
Time frame: From start of maintenance therapy until death from any cause or last follow-up, assessed up to 10 years
Progression-Free Survival
Time frame: From start of maintenance therapy until disease progression, death or last follow-up, assessed up to 10 years
Best Response to Maintenance Therapy
Time frame: From start of maintenance therapy until disease progression or end of maintenance, assessed up to 10 years
Survival Rate at 6 Months and 1, 2, 3, 4 and 5 Years
Time frame: 6 months and 1, 2, 3, 4 and 5 years after diagnosis
Number of Patients With Adverse Drug Reactions During Maintenance Therapy
Time frame: From start of maintenance therapy until end of maintenance, assessed up to 10 years
Cancer-Specific Mortality
Time frame: From diagnosis until death or last follow-up, assessed up to 10 years
Plan to share: No — Individual participant data will not be shared. Data are obtained from a retrospective review of medical records without individual informed consent and are protected under Colombian personal data protection law (Law 1581 of 2012) and data confidentiality agreements between the participating institutions. Aggregated results will be published in a peer-reviewed journal.
Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundación Santa Fe de Bogota